Results are consistent with recent studies showing that SphK inhibitors significantly abrogate colitic damage and reduce the expression of IL-6 and COX-2 [27], and with the enhancement of colitis severity and inflammation by deletion of S1PL in DSS mouse models [5]. This evidence concerns the gene SGPL1 and colitis.